Laboratory interpretation
Syphilis titers: count dilutions, then interpret the patient
A change from 1:32 to 1:8 can be misread if the denominators are treated as ordinary subtraction. Syphilis monitoring uses dilution steps, and the method matters. A numerical change belongs beside stage, timing, treatment history and symptoms before it becomes a clinical conclusion.
Sources checked October 7, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Use the two test types correctly
CDC describes a presumptive serologic diagnosis using a nontreponemal test such as RPR or VDRL and a treponemal test. One type alone is insufficient. Preserve the actual test names, results and history rather than calling every reactive screening result a new active infection.
In the traditional algorithm, reactive nontreponemal testing needs treponemal confirmation because false positives occur. Reverse-sequence testing has separate steps for discordant results. A screening algorithm and a monitoring measure have different jobs; avoid using one result to answer every question.
Count ratios, not subtraction
From 1:32 to 1:16 to 1:8 is two dilution steps, a fourfold decrease. From 1:8 to 1:16 to 1:32 is a fourfold increase. A change from 1:16 to 1:8 is one step and only twofold. Write the direction and factor explicitly.
CDC considers a fourfold change clinically significant when results use the same serologic test, preferably from the same manufacturer. This numerical criterion alone does not authorize a declaration of cure, reinfection or treatment failure without elapsed time and clinical context.
Keep the assay stable
Sequential results should use the same testing method, preferably in the same laboratory. Quantitative RPR and VDRL results cannot be directly compared because the methods differ; CDC notes that RPR titers often run slightly higher. A lower VDRL after an RPR is not automatically a response.
If the method changed, state the limitation before calculating a response. Recover the prior reports and comparable monitoring plan. An exact-looking ratio drawn from unlike assays can mislead more than a plainly stated missing fact.
Separate persistent antibodies from failure
Most people with reactive treponemal tests remain reactive for life after treatment. Nontreponemal titers generally decrease but can remain reactive or decline less than expected. Use stage, elapsed time, symptoms, treatment and subsequent exposures to interpret the pattern.
The general source does not supply one follow-up interval for every stage. Use stage-specific guidance for monitoring and treatment. Neurologic, ocular or otic symptoms require their own evaluation; a stable titer does not settle those clinical questions.
A worked case
Using the same laboratory and RPR assay, a patient moves from 1:32 to 1:8 after treatment. A treponemal test remains reactive. What is established numerically, and what remains unresolved?
- Count two dilution steps: a fourfold decrease.
- Persistent treponemal reactivity can follow adequate treatment.
- Recover stage, time since treatment, symptoms and exposure before declaring an outcome.
Answer: There is a fourfold RPR decrease, but these results alone do not prove cure or determine the next treatment.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. RPR 1:16 to RPR 1:8: fourfold or twofold?
Twofold, one dilution step.
2. Can baseline RPR 1:32 be directly compared with later VDRL 1:8?
No. The numerical results are not interchangeable for that comparison.
3. Does a reactive treponemal test after treatment alone prove failure?
No. Reactivity commonly persists after adequate treatment.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.